Company Overview
Archit Organosys Limited, a chemical manufacturing company, has announced significant corporate actions alongside its FY26 financial results. The company reported strong performance with 11.77% revenue growth to ₹14,383.71 lakhs and 45.8% profit increase to ₹803.21 lakhs, maintaining a healthy debt-equity ratio of 0.33.
Corporate Actions
Preferential Issue for Acquisition: The board approved a preferential issue of 3,72,48,344 equity shares at ₹65 per share (₹10 face value + ₹55 premium) to acquire 92.20% stake in Archit Life Science Limited. The issue price exceeds the SEBI-mandated floor price of ₹63.87, valuing the acquisition at ₹242.11 crore. Post-allotment, promoter holding will increase from 65.88% to 70.57% with no change in company control.
Lock-in Requirements: Shares allotted to promoters will have an 18-month lock-in period, while non-promoter shares will be locked in for 6 months from trading approval date.
AGM and Dividend
The 33rd Annual General Meeting is scheduled for September 30, 2026, to be held via video conferencing. Key agenda items include approval of financial statements, declaration of dividend of Re. 1 per share, and ratification of various corporate actions including the preferential issue and acquisition.
Capital Structure Changes
The company proposes to increase authorized share capital from ₹25 crores to ₹60 crores to accommodate the preferential issue and future growth plans.
Financial Position
As of March 31, 2026, the company maintained a strong financial position with total assets of ₹12,667.17 lakhs, net worth of ₹7,623.27 lakhs, and cash equivalents of ₹137.41 lakhs. Key ratios include current ratio of 1.41 times, net profit ratio of 6.02%, and return on net worth of 10.54%.
Future Outlook
The company is expanding into pharmaceutical lines by importing bulk drugs and marketing in local markets. Products are sold across India and exported to USA, Europe, Latin America, Asian countries, and South Africa, positioning the company to benefit from the chemical industry's projected growth to $255 billion by 2030.